A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA
Latest Information Update: 04 Oct 2024
At a glance
- Drugs CNP 104 (Primary)
- Indications Primary biliary cirrhosis
- Focus Adverse reactions; First in man; Pharmacodynamics; Proof of concept
- Sponsors Cour Pharmaceutical Development
- 30 Sep 2024 Results published in the COUR Pharmaceuticals Media Release
- 11 Jun 2024 Planned End Date changed from 30 Dec 2025 to 30 Jan 2026.
- 11 Jun 2024 Planned primary completion date changed from 30 Dec 2025 to 30 Jan 2026.